FROM FDA BY MEDSCAPE

MEDSCAPE KEEPS US INFORMED! FDA Approvals > Heartwire

FDA Refuses Rivaroxaban Stent-Thrombosis Indication for Now

Steve Stiles

DisclosuresJun 28, 2013

 

Topic Alert

Receive an email from Medscape whenever new articles on this topic are available.

• Add Acute Coronary Syndrome (ACS) to My Topic Alert

Drug & Reference Information

• Percutaneous Transcatheter Treatment of Deep Venous Thrombosis
• Heparin Use in Deep Venous Thrombosis
• Deep Venous Thrombosis Risk Stratification

RARITAN, New Jersey — The FDA has given a complete response letter (CRL) to one of the companies behind rivaroxaban (Xarelto, Bayer Pharma/Janssen Pharmaceuticals) indicating that it won't, for now, approve the oral factor Xa inhibitor for prevention of stent thrombosis in patients with acute coronary syndromes [1].

A therapy that has been shown to improve bone pain in as little as 3 months in patients with Type 1 Gaucher disease

This therapy has also been shown to improve bone mineral density after 24 months of treatment.

View data

Information from Industry

As noted in a statement today from Janssen, approval for that indication had been sought in a supplemental new drug application (sNDA) based largely on the ATLAS ACS 2 TIMI 51 trial. The CRL, which signals that the FDA wants to see additional data before it will further consider the sNDA, follows others that it sent the companies regarding approval of rivaroxaban for patients with ACS, as reported by heartwire . The drug is already approved for ACS secondary prevention in Europe.
"We remain confident in the results of the ATLAS ACS 2 TIMI 51 trial and are in ongoing discussions with the FDA regarding this sNDA," said a Janssen official in the company's press release on the stent-thrombosis CRL.
The agency has already approved rivaroxaban, an oral factor Xa inhibitor, for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for preventing recurrences, for reducing the risk of DVT and PE after knee- or hip-replacement surgery, and for cutting the risk of stroke in nonvalvular atrial fibrillation.